PRODUCTS

AbbVie’s anti-cancer drug Veliparib (Veliparib, ABT-888) is a new type of polyadenylate diphosphate ribose polymerase (PARP) inhibitor, and polyadenylate diphosphate ribose transferase (poly ADP-ribose polymerase (PARP) is a DNA repair enzyme that plays a key role in the DNA repair pathway. Veliparib is a new type of highly selective PARP inhibitor that works by interfering with the DNA repair process in cells, which will make tumors more sensitive to chemotherapeutics that damage DNA.

The drug is currently undergoing clinical trials in the United States for the treatment of different tumors, including three phase 3 clinical trials just launched this year for the treatment of (1) triple-negative breast cancer (U.S. clinical trial number NCT02032277); (2) and Non-small cell lung cancer (NSCLC, U.S. clinical trial number NCT02106546); (3) HER2-negative, BRCA1/2-positive breast cancer (U.S. clinical trial number NCT02163694).